Obesity in autoimmune diseases: Not a passive bystander

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 981-1000

  Versini, Mathilde ^a,b   Jeandel, Pierre Yves ^b   Rosenthal, Eric ^b   Shoenfeld, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adipokines; Autoimmune diseases; Autoimmunity; Obesity; Overweight; White adipose tissue

Indexed keywords

ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; HASHIMOTO DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; OBESITY; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; WHITE ADIPOSE TISSUE; ANIMAL; COMPLICATION; IMMUNOLOGY; INFLAMMATION; THYROID GLAND;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; OBESITY; RISK FACTORS; THYROID GLAND;

EID: 84922609257     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.07.001     Document Type: Review

References (364)

1. Pedersen J.K., Svendsen A.J., Hørslev-Petersen K. Incidence of rheumatoid arthritis in the southern part of Denmark from 1995 to 2001. Open Rheumatol J Jan 2007, 1:18-23.
2. Patterson C.C., Dahlquist G.G., Gyürüs E., Green A., Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet Jul 13 2009, 373(9680):2027-2033.
3. Zandman-Goddard G., Shoenfeld Y. Parasitic infection and autoimmunity. Lupus Nov 2009, 18(13):1144-1148.
4. De Carvalho J.F., Pereira R.M.R., Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed) Jan 2009, 1:501-509.
5. Bogdanos D.P., Smyk D.S., Invernizzi P., Rigopoulou E.I., Blank M., Pouria S., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev May 2013, 12(7):726-740.
6. Agmon-Levin N., Theodor E., Segal R.M., Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol Oct 2013, 45(2):256-266.
7. Doria A., Sarzi-Puttini P., Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev Oct 2008, 8(1):1-4.
8. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol Aug 2009, 30(8):409-414.
9. Moroni L., Bianchi I., Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev May 2012, 11(6-7):A386-A392.
10. Van der Meer J.W., Netea M.G. A salty taste to autoimmunity. N Engl J Med Jun 27 2013, 368(26):2520-2521.
11. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA Jan 20 2010, 303(3):235-241.
12. World Health Organization Overweight/obesity: overweight by country. Global Health Observatory Data Repository 2008 2013 2013.
13. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014, 220(2):T47-T59.
14. Gómez R., Conde J., Scotece M., Gómez-Reino J.J., Lago F., Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol. Sep 2011, 7(9):528-536. Nature Publishing Group.
15. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest Dec 2003, 112(12):1796-1808.
16. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med Aug 2009, 15(8):914-920.
17. Arai S., Maehara N., Iwamura Y., Honda S., Nakashima K., Kai T., et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013, 3(4):1187-1198. The Authors.
18. Arai S., Miyazaki T. Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin Immunopathol Jan 2013, 36(1):3-12.
19. Miyazaki T., Hirokami Y., Matsuhashi N., Takatsuka H., Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med Jan 18 1999, 189(2):413-422.
20. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev Jun 2014, 13(6):668-677.
21. Winer S., Paltser G., Chan Y., Tsui H., Engleman E., Winer D., et al. Obesity predisposes to Th17 bias. Eur J Immunol Oct 2009, 39(9):2629-2635.
22. Ahmed M., Gaffen S. IL-17 inhibits adipogenesis in part bia C/EBP-alpha, PPAR-gamma and Krüppel-like factors. Cytokine 2014, 61(3):898-905.
23. Ahmed M., Gaffen S. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev 2012, 21(6):449-453.
24. Manzel A., Muller D.N., Hafler D.A., Kleinewietfeld M. Role of "western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep 2014, 14(1):404.
25. Brown K., DeCoffe D., Molcan E., Gibson D.L. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients Aug 2012, 4(11):1552-1553.
26. Soskić S., Stokić E., Isenović E.R. The relationship between vitamin D and obesity. Curr Med Res Opin Jul 2014, 30(6):1197-1199.
27. Schoindre Y., Terrier B., Kahn J.-E., Saadoun D., Souberbielle J.-C., Benveniste O., et al. Vitamin D and autoimmunity. First part: fundamental aspects. La Rev Méd Interne Mar 2012, 33(2):80-86.
28. Yang C.-Y., Leung P.S.C., Adamopoulos I.E., Gershwin M.E. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol Oct 2013, 45(2):217-226.
29. Pludowski P., Holick M.F., Pilz S., Wagner C.L., Hollis B.W., Grant W.B., et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev Aug 2013, 12(10):976-989.
30. Lukens J.R., Dixit V.D., Kanneganti T.-D. Inflammasome activation in obesity-related inflammatory diseases and autoimmunity. Discov Med Jul 2011, 12(62):65-74.
31. Nishimura S., Manabe I., Takaki S., Nagasaki M., Otsu M., Yamashita H., et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab. Oct 22 2013, 18(5):759-766. Elsevier Inc.
32. Rakhshandehroo M., Kalkhoven E., Boes M. Invariant natural killer T cells in adipose tissue: novel regulators of immune-mediated metabolic disease. Cell Mol Life Sci 2013, 70(24):4711-4727.
33. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009, 43(4):157-168.
34. Iikuni N., Lam Q., Lu L., Matarese G., La Cava A. Leptin and inflammation. Curr Immunol Rev 2010, 4(2):70-79.
35. Krysiak R., Handzlik-Orlik G., Okopien B. The role of adipokines in connective tissue diseases. Eur J Nutr Aug 2012, 51(5):513-528.
36. Derdemezis C.S., Voulgari P.V., Drosos A.A., Kiortsis D.N. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship?. Clin Exp Rheumatol 2011, 29(4):712-727.
37. Stavropoulos-kalinoglou A., Metsios G.S., Koutedakis Y., Kitas G.D. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50(3):450-462.
38. Li L., Wu L.-L. Adiponectin and interleukin-6 in inflammation-associated disease. Vitam Horm Jan 2012, 90:375-395.
39. Sun Y., Xun K., Wang C., Zhao H., Bi H., Chen X., et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther Jan 2009, 27(1):59-75.
40. Toussirot E., Gaugler B., Bouhaddi M., Nguyen N.U., Saas P., Dumoulin G. Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediators Inflamm Jan 2010.
41. Stofkova A. Resistin and Visfatin: regulators of insulin sensitivity inflammation and immunity. Endocr Regul 2010, 44(1):25-36.
42. Kourilovitch M., Galarza-Maldonado C., Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun 2014, 48-49:26-30.
43. Myasoedova E., Crowson C.S., Kremers H.M., Therneau T.M., Gabriel S.E. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum Jul 2010, 62(6):1576-1582.
44. Neovius M., Simard J.F., Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis May 2011, 70(4):624-629.
45. Roubenoff R., Roubenoff R.A., Cannon J.G., Kehayias J.J., Zhuang H., Dawson-Hughes B., et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest Jun 1994, 93(6):2379-2386.
46. Kremers H.M., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum Nov 2004, 50(11):3450-3457.
47. Crowson C.S., Liao K.P., Davis J.M., Solomon D.H., Matteson E.L., Knutson K.L., et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J Oct 2013, 166(4):622-628. [e1].
48. Landsberg L., Aronne L.J., Beilin L.J., Burke V., Igel L.I., Lloyd-Jones D., et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment-a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) Jan 2013, 21(1):8-24.
49. Chen Y., Copeland W.K., Vedanthan R., Grant E., Lee J.E., Gu D., et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ Jan 2013, 347:f5446.
50. Symmons D.P., Bankhead C.R., Harrison B.J., Brennan P., Barrett E.M., Scott D.G., et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk. England Arthritis Rheum Dec 1997, 40(11):1955-1961.
51. Pedersen M., Jacobsen S., Klarlund M., Pedersen B.V., Wiik A., Wohlfahrt J., et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther Jan 2006, 8(4):R133.
52. Lahiri M., Morgan C., Symmons D.P.M., Bruce I.N. Modifiable risk factors for RA: prevention, better than cure?. Rheumatology (Oxford) 2012, 51(3):499-512.
53. Crowson C.S., Matteson E.L., Davis J.M.G.S. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014, 65(1):71-77.
54. De Hair M.J., Landewé R.B., Van De Sande M.G., Van Schaardenburg D., Van Baarsen L.G.M., Gerlag D.M., et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013, 72(10):1654-1658.
55. Wesley A., Bengtsson C., Elkan A., Klareskog L., Alfredsson L., Wedre S. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res (Hoboken) 2013, 65(1):107-112.
56. Lahiri M., Luben R.N., Morgan C., Bunn D.K., Marshall T., Lunt M., et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register-the EPIC-2-NOAR Study). Ann Rheum Dis Jan 2014, 73(1):219-226.
57. Lu B., Hiraki L., Sparks J.A., Malspeis S., Chen C.-Y., Awosogba J.A., et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis Jul 23 2014, [Online First]. 10.1136/annrheumdis-2014-205459.
58. Kaipiainen-Seppanen O., Kautiainen H. Declining trend in the incidence of rheumatoid factor-positive rheumatoid arthritis in Finland 1980-2000. J Rheumatol Dec 2006, 33(11):2132-2138.
59. Vessey M.P., Villard-Mackintosh L., Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception May 1987, 35(5):457-464.
60. Hernández Avila M., Liang M.H., Willett W.C., Stampfer M.J., Colditz G.A., Rosner B., et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology Jul 1990, 1(4):285-291.
61. Voigt L.F., Koepsell T.D., Nelson J.L., Dugowson C.E., Daling J.R. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology Oct 1994, 5(5):525-532.
62. Uhlig T., Hagen K.B., Kvien T.K. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol Jan 1999, 26(1):47-54.
63. Cerhan J.R., Saag K.G., Criswell L.A., Merlino L.A., Mikuls T.R. Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol Mar 2002, 29(2):246-254.
64. Bartfai T., Waalen J., Buxbaum J.N. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis?. J Rheumatol Mar 2007, 34(3):488-492.
65. Rodríguez L.A.G., Tolosa L.B., Ruigómez A., Johansson S., Wallander M.-A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009, 38(3):173-177.
66. Stavropoulos-Kalinoglou A., Metsios G.S., Koutedakis Y., Nevill A.M., Douglas K.M., Jamurtas A., et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis Oct 2007, 66(10):1316-1321.
67. Ajeganova S., Andersson M.L., Hafström I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken) Jan 2013, 65(1):78-87.
68. Hollingworth P., Melsom R.D., Scott J.T. Measurement of radiographic joint space in the rheumatoid knee: correlation with obesity, disease duration, and other factors. Rheumatol Rehabil Mar 1982, 21(1):9-14.
69. García-Poma A., Segami M.I., Mora C.S., Ugarte M.F., Terrazas H.N., Rhor E.A., et al. Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clin Rheumatol Nov 2007, 26(11):1831-1835.
70. Kremers H.M., Crowson C.S., Therneau T.M., Roger V.L., Gabriel S.E. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum Aug 2008, 58(8):2268-2274.
71. Stavropoulos-Kalinoglou A., Metsios G.S., Panoulas V.F., Nevill A.M., Jamurtas A.Z., Koutedakis Y., et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol Apr 2009, 28(4):439-444.
72. Jawaheer D., Olsen J., Lahiff M., Forsberg S., Lähteenmäki J., da Silveira I.G., et al. Gender, body mass index and rheumatoid arthritis disease activity: results from the QUEST-RA Study. Clin Exp Rheumatol. 2010, 28(4):454-461.
73. Westhoff G., Rau R., Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum Nov 2007, 56(11):3575-3582.
74. Caplan L., Davis L.A., Bright C.M., Kerr G.S., Lazaro D.M., Khan N.A., et al. Body mass index and the rheumatoid arthritis swollen joint count: an observational study. Arthritis Care Res (Hoboken) Jan 2013, 65(1):101-106.
75. Choe J.Y., Bae J., Lee H., Park S., Kim S. Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. Clin Rheumatol 2014, 33(4):485-492.
76. Wolfe F., Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(10):1471-1479.
77. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alén J., Hørslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther Jan 2008, 10(2):R30.
78. Escalante A., Haas R.W., del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med Jul 25 2005, 165(14):1624-1629.
79. Otero M., Lago R., Gomez R., Lago F., Dieguez C., Gómez-Reino J.J., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis Oct 2006, 65(9):1198-1201.
80. Lee S.-W., Park M.-C., Park Y.-B., Lee S.-K. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int May 2007, 27(6):537-540.
81. Yoshino T., Kusunoki N., Tanaka N., Kaneko K., Kusunoki Y., Endo H., et al. Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Intern Med Jan 2011, 50(4):269-275.
82. Olama S.M., Senna M.K., Elarman M. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol Int Mar 2012, 32(3):683-690.
83. Xibillé-Friedmann D., Bustos-Bahena C., Hernàndez-Gongora S., Burgos-Vargas R., Montiel-Hernàndez J. Two-year follow-up of plasma leptin and other cytokines in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69(5):9-11.
84. Schäffler A., Ehling A., Neumann E., Herfarth H., Tarner I., Schölmerich J., et al. Adipocytokines in synovial fluid. JAMA Oct 1 2003, 290(13):1709-1710.
85. Chen X., Lu J., Bao J., Guo J., Shi J., Wang Y. Adiponectin: a biomarker for rheumatoid arthritis?. Cytokine Growth Factor Rev Mar 2013, 24(1):83-89.
86. Fadda S.M.H., Gamal S.M., Elsaid N.Y., Mohy A.M. Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression. Z Rheumatol Aug 2013, 72(6):594-600.
87. Senolt L., Housa D., Vernerová Z., Jirásek T., Svobodová R., Veigl D., et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis Apr 2007, 66(4):458-463.
88. Migita K., Maeda Y., Miyashita T., Kimura H., Nakamura M., Ishibashi H., et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006, 24(6):698-701.
89. Forsblad d'Elia H., Pullerits R., Carlsten H., Bokarewa M. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) Jul 2008, 47(7):1082-1087.
90. Kontunen P., Vuolteenaho K., Nieminen R., Lehtimäki L., Kautiainen H., Kesäniemi Y., et al. Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheumatol Jan 2011, 40(4):256-262.
91. Straburzyńska-Lupa A., Nowak A., Pilaczyńska-Szcześniak Ł., Straburzyńska-Migaj E., Romanowski W., Karolkiewicz J., et al. Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 2010, 28(1):19-24.
92. Alkady E.A.M., Ahmed H.M., Tag L., Abdou M.A. Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients. Relation to disease activity. Z Rheumatol Oct 2011, 70(7):602-608.
93. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R.E., Gay S., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum Oct 2007, 56(9):2829-2839.
94. Rho Y.H., Solus J., Sokka T., Oeser A., Chung C.P., Gebretsadik T., et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum Jul 2009, 60(7):1906-1914.
95. Busso N., So A., Chobaz-Péclat V., Morard C., Martinez-Soria E., Talabot-Ayer D., et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol Jan 15 2002, 168(2):875-882.
96. Busso N., Karababa M., Nobile M., Rolaz A., Van Gool F., Galli M., et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One Jan 2008, 3(5):e2267.
97. Evans L., Williams A.S., Hayes A.J., Jones S.A., Nowell M. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthrit. Arthritis Rheum Jul 2011, 63(7):1866-1877.
98. Kaufmann J., Kielstein V., Kilian S., Stein G., Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol Dec 2003, 30(11):2350-2355.
99. Van der Helm-van Mil A., van der Kooij S., Allaart C., Toes R., Huizinga T. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis Jun 2008, 67(6):769-774.
100. De Rooy D., van der Linden M.P., Knevel R., Huizinga T.W., van der Helm-van Mil A.H. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) Jan 2011, 50(1):93-100.
101. Tremollieres F.A., Pouilles J.M., Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab Oct 1993, 77(3):683-686.
102. Rohrmann S., Shiels M.S., Lopez D.S., Rifai N., Nelson W.G., Kanarek N., et al. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control Aug 2011, 22(8):1141-1151.
103. Tan W., Wang F., Zhang M., Guo D., Zhang Q., He S. High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. Semin Arthritis Rheum Jul 2009, 38(6):420-427.
104. Matsui H., Tsutsumi A., Sugihara M., Suzuki T., Iwanami K., Kohno M., et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Ann Rheum Dis May 2008, 67(4):571-572.
105. Klein-wieringa I.R., Van Der Linden M.P.M., Knevel R., Kwekkeboom J.C., Van Beelen E., Huizinga T.W.J., et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011, 63(9):2567-2574.
106. Giles J., van der Heijde D., Bathon J. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013, 70(9):1562-1568.
107. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol May 1 2005, 174(9):5789-5795.
108. Gómez R., Scotece M., Conde J., Gómez-Reino J.J., Lago F., Gualillo O. Adiponectin and leptin increase IL-8 production in human chondrocytes. Ann Rheum Dis Dec 2011, 70(11):2052-2054.
109. Bao J., Chen W., Feng J., Hu P., Shi Z., Wu L. Leptin plays a catabolic role on articular cartilage. Mol Biol Rep Oct 2010, 37(7):3265-3272.
110. Tong K.-M., Chen C.-P., Huang K.-C., Shieh D.-C., Cheng H.-C., Tzeng C.-Y., et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem May 2011, 112(5):1431-1440.
111. Lago R., Gomez R., Otero M., Lago F., Gallego R., Dieguez C., et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage Oct 2008, 16(9):1101-1109.
112. Kusunoki N., Kitahara K., Kojima F., Tanaka N., Kaneko K., Endo H., et al. Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum Jul 2010, 62(6):1641-1649.
113. Frommer K.W., Schäffler A., Büchler C., Steinmeyer J., Rickert M., Rehart S., et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?. Ann Rheum Dis Oct 2012, 71(10):1724-1732.
114. Heimans L., van den Broek M., le Cessie S., Siegerink B., Riyazi N., Han K.H., et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (Hoboken) Aug 2013, 65(8):1235-1242.
115. Klaasen R., Wijbrandts C.A., Gerlag D.M., Tak P.P. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum Mar 2011, 63(2):359-364.
116. Smolen J., Szumski A., Koening A., Jones T. Impact of body mass index on response to etanercept therapy in subjects with moderate active rheumatoid arthritis in the PRESERVE trial. Arthritis Rheum 2011, 63:S156-S157. [Abstract Supplement].
117. González-gay M.A., González-juanatey C. Rheumatoid arthritis: obesity impairs efficacy of anti-TNF therapy in patients with RA. Nat Rev Rheumatol. 2012, 8(11):641-642. Nature Publishing Group.
118. Gremese E., Carletto A., Padovan M., Atzeni F., Raffeiner B., Giardina A.R., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013, 65(1):94-100.
119. Sandberg M.E.C., Bengtsson C., Källberg H., Wesley A., Klareskog L., Alfredsson L., et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis May 12 2014.
120. Derdemezis C.S., Filippatos T.D., Voulgari P.V., Tselepis A.D., Drosos A.A., Kiortsis D.N. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol Oct 2009, 23(5):595-600.
121. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Garcia-Unzueta M.T., Berja A., Miranda-Filloy J.A., de Matias J.M., et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol. 2010, 28(1):56-62.
122. Gonzalez-Gay M.A., Garcia-Unzueta M.T., Berja A., Gonzalez-Juanatey C., Miranda-Filloy J.A., Vazquez-Rodriguez T.R., et al. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol. 2009, 27(2):222-228.
123. Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev Jun 2012, 11(8):593-595.
124. Gatto M., Zen M., Ghirardello A., Bettio S., Bassi N., Iaccarino L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev Feb 2013, 12(4):523-536.
125. Oliver J.E., Silman A.J. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther Jan 2009, 11(3):223.
126. Harpsøe M.C., Basit S., Andersson M., Nielsen N.M., Frisch M., Wohlfahrt J., et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol 2014, 1-13.
127. Amarilyo G., Iikuni N., Shi F., Liu A., Matarese G., La A. Leptin promotes lupus T-cell autoimmunity. Clin Immunol. 2013, 149(3):530-533. Elsevier Inc.
128. Fujita Y., Fujii T., Mimori T., Sato T., Nakamura T., Iwao H., et al. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp- Fas lpr mice. J Immunol 2014, 192(3):979-984.
129. Yu Y., Liu Y., Shi F.-D., Zou H., Matarese G., La Cava A. Leptin-induced ROR-gamma-t expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol 2014, 190(7):3054-3058.
130. Liu Y., Yu Y., Matarese G., La Cava A. Fasting-induced hypoletinemia expands functional regulatory T cells in systemic lupus erythematosus. J Immunol 2013, 188(5):2070-2073.
131. Katz P., Gregorich S., Yazdany J., Trupin L., Julian L., Yelin E., et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) Mar 2011, 63(2):261-268.
132. Borges M.C., dos Santos F de MM, Telles R.W., Lanna C.C.D., Correia M.I.T.D. Nutritional status and food intake in patients with systemic lupus erythematosus. Nutrition. 2012, 28(11-12):1098-1103.
133. Sinicato N.A., Postal M., Peres F.A., Peliçari K.D.O., Marini R., De Oliveira A., et al. Obesity and cytokines in childhood-onset systemic lupus erythematosus. J Immunol Res 2014.
134. Rizk A., Gheita T.A., Nassef S., Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. Int J Rheum Dis Jul 2012, 15(3):261-267.
135. Chaiamnuay S., Bertoli A.M., Fernández M., Apte M., Vilá L.M., Reveille J.D., et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. J Clin Rheumatol Jul 2007, 13(3):128-133.
136. Sada K.-E., Yamasaki Y., Maruyama M., Sugiyama H., Yamamura M., Maeshima Y., et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol Aug 2006, 33(8):1545-1552.
137. Vadacca M., Margiotta D., Rigon A., Cacciapaglia F., Coppolino G., Amoroso A., et al. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol Feb 2009, 36(2):295-297.
138. Kim H., Choi G., Jeon J., Yoon J., Sung J., Suh C. Leptin and ghrelin in Korean systemic lupus erythematosus. Lupus 2010, 19(2):170-174.
139. Al M., Ng L., Tyrrell P., Bargman J., Bradley T., Silverman E. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) May 2009, 48(5):497-501.
140. Garcia-Gonzalez A., Gonzalez-Lopez L., Valera-Gonzalez I.C., Cardona-Muñoz E.G., Salazar-Paramo M., González-Ortiz M., et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int Aug 2002, 22(4):138-141.
141. Chung C.P., Long A.G., Solus J.F., Rho Y.H., Oeser A., Raggi P., et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus Aug 2009, 18(9):799-806.
142. De Sanctis J.B., Zabaleta M., Bianco N.E., Garmendia J.V., Rivas L. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity May 2009, 42(4):272-274.
143. Wisłowska M., Rok M., Stepień K., Kuklo-Kowalska A. Serum leptin in systemic lupus erythematosus. Rheumatol Int Mar 2008, 28(5):467-473.
144. Parker J., Menn-Josephy H., Laskow B., Takemura Y., Aprahamian T. Modulation of lupus phenotype by adiponectin deficiency in autoimmune mouse models. J Clin Immunol 2012, 31(2):167-173.
145. Oeser A., Chung C.P., Asanuma Y., Avalos I., Stein C.M. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum Dec 2005, 52(11):3651-3659.
146. Gilbert E.L., Ryan M.J. High dietary fat promotes visceral obesity and impaired endothelial function in female mice with systemic lupus erythematosus. Gend Med 2012, 8(2):150-155.
147. Boström E., Ekstedt M., Kechagias S., Sjöwall C., Bokarewa M.I., Almer S. Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. Clin Immunol 2011, 74(5):463-470.
148. Baker J.F., Morales M., Qatanani M., Nackos E., Lazar M.A., Teff K., et al. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 2011, 38(11):2369-2375.
149. Aprahamian T., Bonegio R.G., Richez C., Yasuda K., Chiang L.-K., Sato K., et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol Jan 1 2009, 182(1):340-346.
150. Rovin B.H., Song H., Hebert L.A., Nadasdy T., Nadasdy G., Birmingham D.J., et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int Oct 2005, 68(4):1825-1833.
151. Katz P., Julian L., Tonner M.C., Yazdany J., Trupin L., Yelin E., et al. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013, 64(4):502-510.
152. Katz P., Yazdany J., Julian L., Trupin L., Margaretten M., Yelin E., et al. The impact of obesity on functioning among women with SLE. Arthritis Care Res (Hoboken) 2011, 63(10):1357-1364.
153. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology Jul 8 2003, 61(1):76-80.
154. Gunstad J., Spitznagel M.B., Keary T.A., Glickman E., Alexander T., Karrer J., et al. Serum leptin levels are associated with cognitive function in older adults. Brain Res Sep 16 2008, 1230:233-236.
155. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol Aging Sep 2009, 30(9):1483-1489.
156. Chaiamnuay S., Bertoli A.M., Roseman J.M., McGwin G., Apte M., Durán S., et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis May 2007, 66(5):618-622.
157. Nikpour M., Urowitz M.B., Gladman D.D. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep Aug 2009, 11(4):248-254.
158. Knight J.S., Kaplan M.J. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol Sep 2013, 25(5):597-605.
159. Chung C.P., Avalos I., Oeser A., Gebretsadik T., Shintani A., Raggi P., et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis Feb 2007, 66(2):208-214.
160. McMahon M., Skaggs B.J., Sahakian L., Grossman J., FitzGerald J., Ragavendra N., et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis Sep 2011, 70(9):1619-1624.
161. Almehed K., d'Elia H.F., Bokarewa M., Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther Jan 2008, 10(1):R15.
162. Cassinotti A., Sarzi-Puttini P., Fichera M., Shoenfeld Y., de Franchis R., Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):1-2.
163. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet Nov 3 2012, 380(9853):1590-1605.
164. Ordás I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet Nov 3 2012, 380(9853):1606-1619.
165. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med Nov 19 2009, 361(21):2066-2078.
166. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology May 2011, 140(6):1785-1794.
167. Chan S.S.M., Luben R., Olsen A., Tjonneland A., Kaaks R., Teucher B., et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC study). Am J Gastroenterol Apr 2013, 108(4):575-582.
168. Mendall M.A., Gunasekera A.V., John B.J., Kumar D. Is obesity a risk factor for Crohn's disease?. Dig Dis Sci Mar 2011, 56(3):837-844.
169. Hou J.K., Abraham B., El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol Apr 2011, 106(4):563-573.
170. Steed H., Walsh S., Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes Facts Jan 2009, 2(6):370-372.
171. Sheehan A.L., Warren B.F., Gear M.W., Shepherd N.A. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg Sep 1992, 79(9):955-958.
172. Paik J., Fierce Y., Treuting P.M., Brabb T., Maggio-price L. High-fat diet-induced obesity exacerbates inflammatory bowel disease in genetically susceptible Mdr1a-/- male mice. J Nutr 2013, 143(8):1240-1247.
173. Teixeira L.G., Leonel A.J., Aguilar E.C., Batista N.V., Alves A.C., Coimbra C.C., et al. The combination of high-fat diet-induced obesity and chronic ulcerative colitis reciprocally exacerbates adipose tissue and colon inflammation. Lipids Health Dis. 2011 Jan, 10(1):204. BioMed Central Ltd.
174. Blain A., Cattan S., Beaugerie L., Carbonnel F., Gendre J.P., Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr Feb 2002, 21(1):51-57.
175. Hass D.J., Brensinger C.M., Lewis J.D., Lichtenstein G.R. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol Apr 2006, 4(4):482-488.
176. Tuzun A., Uygun A., Yesilova Z., Ozel A.M., Erdil A., Yaman H., et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol Apr 2004, 19(4):429-432.
177. Barbier M., Vidal H., Desreumaux P., Dubuquoy L., Bourreille A., Colombel J.-F., et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroentérologie Clin Biol Nov 2003, 27(11):987-991.
178. Ponemone V., Keshavarzian A., Brand M.I., Saclarides T., Abcarian H., Cabay R.J., et al. Apoptosis and inflammation: role of adipokines in inflammatory bowel disease. Clin Transl Gastroenterol. Jan 2010, 1:e1. Nature Publishing Group.
179. Sitaraman S., Liu X., Charrier L., Gu L.H., Ziegler T.R., Gewirtz A., et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J Apr 2004, 18(6):696-698.
180. Hoda M.R., Scharl M., Keely S.J., McCole D.F., Barrett K.E. Apical leptin induces chloride secretion by intestinal epithelial cells and in a rat model of acute chemotherapy-induced colitis. Am J Physiol Gastrointest Liver Physiol May 2010, 298(5):G714-G721.
181. Siegmund B., Lear-Kaul K.C., Faggioni R., Fantuzzi G. Leptin deficiency, not obesity, protects mice from Con A-induced hepatitis. Eur J Immunol Feb 2002, 32(2):552-560.
182. Siegmund B., Sennello J.A., Jones-Carson J., Gamboni-Robertson F., Lehr H.A., Batra A., et al. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut Jul 2004, 53(7):965-972.
183. Valentini L., Wirth E.K., Schweizer U., Hengstermann S., Schaper L., Koernicke T., et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition Feb 2009, 25(2):172-181.
184. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis Feb 2006, 12(2):100-105.
185. Paul G., Schäffler A., Neumeier M., Fürst A., Bataillle F., Buechler C., et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis Jun 2006, 12(6):471-477.
186. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol Mar 1 2007, 178(3):1748-1758.
187. Nishihara T., Matsuda M., Araki H., Oshima K., Kihara S., Funahashi T., et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology Sep 2006, 131(3):853-861.
188. Fayad R., Pini M., Sennello J.A., Cabay R.J., Chan L., Xu A., et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology Feb 2007, 132(2):601-614.
189. Pini M., Gove M.E., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency does not affect development and progression of spontaneous colitis in IL-10 knockout mice. Am J Physiol Gastrointest Liver Physiol Feb 2009, 296(2):G382-G387.
190. Gove M.E., Pini M., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency modulates adhesion molecules expression and cytokine production but does not affect disease severity in the transfer model of colitis. Cytokine Aug 2009, 47(2):119-125. Elsevier Ltd.
191. Rodrigues V.S., Milanski M., Fagundes J.J., Torsoni A.S., Ayrizono M.L., Nunez C.E., et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immunol Dec 2012, 170(3):358-364.
192. Yamamoto K., Kiyohara T., Murayama Y., Kihara S., Okamoto Y., Funahashi T., et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut Jun 2005, 54(6):789-796.
193. Nic Suibhne T., Raftery T.C., McMahon O., Walsh C., O'Morain C., O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis Aug 2013, 7(7):e241-e248.
194. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol Apr 2011, 106(4):674-684.
195. Bultman E., de Haar C., van Liere-Baron A., Verhoog H., West R.L., Kuipers E.J., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther Feb 2012, 35(3):335-341.
196. Harper J.W., Sinanan M.N., Zisman T.L. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis Sep 2013, 19(10):2118-2124.
197. Holtmann M.H., Krummenauer F., Claas C., Kremeyer K., Lorenz D., Rainer O., et al. Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1176 patients. Dig Dis Sci Apr 2010, 55(4):1066-1078.
198. Milo R., Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014, 13(4-5):518-524.
199. World Health Organization Altas of Multiple Sclerosis 2013.
200. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev Mar 2010, 9(5):A387-A394.
201. Sawcer S., Franklin R.J.M., Ban M. Multiple sclerosis genetics. Lancet Neurol July 2014, 13(7):700-709.
202. Lobstein T., Baur L., Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev May 2004, 5(Suppl. 1):4-104.
203. World Health Organization Global strategy on diet. Physical activity and health: a framework to monitor and evaluate implementation 2006, [Geneva].
204. Munger K.L., Chitnis T., Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology Nov 10 2009, 73(19):1543-1550.
205. Hedström A.K., Olsson T., Alfredsson L. High body index before age 20 is associated with increased risk for multiple sclerosis men and women. Mult Scler J 2012, 18(9):1334-1336.
206. Munger K.L., Bentzen J., Laursen B., Stenager E., Koch-henriksen N., Sørensen T.I.A. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler J 2013, 19(10):1323-1329.
207. Langer-gould A., Beaber B.E. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013, 80(6):548-552.
208. Hedström A.K., Lima Bomfim I., Barcellos L., Gianfrancesco M., Schaefer C., Kockum I., et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology Mar 11 2014, 82(10):865-872.
209. Pedersen L.B., Nashold F.E., Spach K.M., Hayes C.E. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res Aug 15 2007, 85(11):2480-2490.
210. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA Dec 20 2006, 296(23):2832-2838.
211. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr Sep 2000, 72(3):690-693.
212. Alemzadeh R., Kichler J., Babar G., Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism Feb 2008, 57(2):183-191.
213. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest Jan 2007, 117(1):175-184.
214. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler Jan 2011, 17(1):2-15.
215. Kraszula L., Jasińska A., Eusebio M.-O., Kuna P., Głabiński A., Pietruczuk M. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2012, 46(1):22-28.
216. Emamgholipour S., Eshaghi S.M., Hossein-nezhad A., Mirzaei K. Adipocytokine profile, cytokine levels and Foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One 2013, 8(10):6-8.
217. Piccio L., Cantoni C., Henderson J.G., Hawiger D., Ramsbottom M., Mikesell R., et al. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur J Immunol 2013, 43(8):2089-2100.
218. Piccio L., Stark J.L., Cross A.H. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol Oct 2008, 84(4):940-948.
219. Bruzzone S., Fruscione F., Morando S., Ferrando T., Poggi A., Garuti A., et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One Jan 2009, 4(11):e7897.
220. Matarese G., Di Giacomo A., Sanna V., Lord G.M., Howard J.K., Di Tuoro A., et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol May 15 2001, 166(10):5909-5916.
221. Sanna V., Di Giacomo A., La Cava A., Lechler R.I., Fontana S., Zappacosta S., et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest Jan 2003, 111(2):241-250.
222. Matarese G., Carrieri P.B., La Cava A., Perna F., Sanna V., De Rosa V., et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A Apr 5 2005, 102(14):5150-5155.
223. De Rosa V., Procaccini C., La Cava A., Chieffi P., Nicoletti G.F., Fontana S., et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest Feb 2006, 116(2):447-455.
224. Matarese G., Procaccini C., De Rosa V. The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis?. J Leukoc Biol 2008, 84(4):893-899.
225. Matarese G., Carrieri P.B., Montella S., De Rosa V., La Cava A. Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol. 2010, 6(8):455-461. Nature Publishing Group.
226. Tuomi T., Santoro N., Caprio S., Cai M., Weng J., Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet Mar 22 2014, 383(9922):1084-1094.
227. Canivell S., Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev 2014, 13(4-5):403-407.
228. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet Jul 2 2011, 378(9785):31-40.
229. Wilkin T.J. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia Jul 2001, 44(7):914-922.
230. Baum J.D., Ounsted M., Smith M.A. Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet Nov 1 1975, 2(7940):866.
231. Islam S.T., Srinivasan S., Craig M.E. Environmental determinants of type 1 diabetes: a role for overweight and insulin resistance. J Paediatr Child Health Jun 3 2014.
232. Rasmussen T., Stene L.C., Samuelsen S.O., Cinek O., Wetlesen T., Torjesen P.A., et al. Maternal BMI before pregnancy, maternal weight gain during pregnancy, and risk of persistent positivity for multiple diabetes-associated autoantibodies in children with the high-risk HLA genotype: the MIDIA study. Diabetes Care Oct 2009, 32(10):1904-1906.
233. McKinney P.A., Parslow R., Gurney K., Law G., Bodansky H.J., Williams D.R. Antenatal risk factors for childhood diabetes mellitus; a case-control study of medical record data in Yorkshire, UK. Diabetologia Aug 1997, 40(8):933-939.
234. Arkkola T., Kautiainen S., Takkinen H.-M., Kenward M.G., Nevalainen J., Uusitalo U., et al. Relationship of maternal weight status and weight gain rate during pregnancy to the development of advanced beta cell autoimmunity in the offspring: a prospective birth cohort study. Pediatr Diabetes Aug 2011, 12(5):478-484.
235. Robertson L., Harrild K. Maternal and neonatal risk factors for childhood type 1 diabetes: a matched case-control study. BMC Public Health Jan 2010, 10:281.
236. Harder T., Roepke K., Diller N., Stechling Y., Dudenhausen J.W., Plagemann A. Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. Am J Epidemiol Jun 15 2009, 169(12):1428-1436.
237. Cardwell C.R., Stene L.C., Joner G., Davis E.A., Cinek O., Rosenbauer J., et al. Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data. Diabetologia Apr 2010, 53(4):641-651.
238. Pedersen C.R., Bock T., Hansen S.V., Hansen M.W., Buschard K. High juvenile body weight and low insulin levels as markers preceding early diabetes in the BB rat. Autoimmunity Jan 1994, 17(4):261-269.
239. Oge A., Isganaitis E., Jimenez-Chillaron J., Reamer C., Faucette R., Barry K., et al. In utero undernutrition reduces diabetes incidence in non-obese diabetic mice. Diabetologia May 2007, 50(5):1099-1108.
240. Larsson H.E., Lynch K., Lernmark B., Nilsson A., Hansson G., Almgren P., et al. Diabetes-associated HLA genotypes affect birthweight in the general population. Diabetologia Aug 2005, 48(8):1484-1491.
241. Verbeeten K.C., Elks C.E., Daneman D., Ong K.K. Association between childhood obesity and subsequent Type 1 diabetes: a systematic review and meta-analysis. Diabet Med Jan 2011, 28(1):10-18.
242. Kibirige M., Metcalf B., Renuka R., Wilkin T.J. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care Oct 2003, 26(10):2865-2870.
243. Knerr I., Wolf J., Reinehr T., Stachow R., Grabert M., Schober E., et al. The "accelerator hypothesis": relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9248 German and Austrian children with type 1 diabetes mellitus. Diabetologia Dec 2005, 48(12):2501-2504.
244. Dabelea D., D'Agostino R.B., Mayer-Davis E.J., Pettitt D.J., Imperatore G., Dolan L.M., et al. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care Feb 2006, 29(2):290-294.
245. Weets I., De Leeuw I.H., Du Caju M.V.L., Rooman R., Keymeulen B., Mathieu C., et al. The incidence of type 1 diabetes in the age group 0-39years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care May 2002, 25(5):840-846.
246. Pundziute-Lyckå A., Dahlquist G., Nyström L., Arnqvist H., Björk E., Blohmé G., et al. The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0-34years group in Sweden 1983-1998. Diabetologia Jun 2002, 45(6):783-791.
247. Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia Jan 2006, 49(1):20-24.
248. Luna R., Garcia-Mayor R.V., Lage M., Andrade M.A., Barreiro J., Pombo M., et al. High serum leptin levels in children with type 1 diabetes mellitus: contribution of age, BMI, pubertal development and metabolic status. Clin Endocrinol (Oxf) Nov 1999, 51(5):603-610.
249. Kirel B., Doğruel N., Korkmaz U., Kiliç F.S., Ozdamar K., Uçar B. Serum leptin levels in type 1 diabetic and obese children: relation to insulin levels. Clin Biochem Aug 2000, 33(6):475-480.
250. Verrotti A., Basciani F., Morgese G., Chiarelli F. Leptin levels in non-obese and obese children and young adults with type 1 diabetes mellitus. Eur J Endocrinol Jul 1998, 139(1):49-53.
251. Imagawa A., Funahashi T., Nakamura T., Moriwaki M., Tanaka S., Nishizawa H., et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care Sep 2002, 25(9):1665-1666.
252. Leth H., Andersen K.K., Frystyk J., Tarnow L., Rossing P., Parving H.-H., et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab Aug 2008, 93(8):3186-3191.
253. Pham M.N., Kolb H., Mandrup-Poulsen T., Battelino T., Ludvigsson J., Pozzilli P., et al. Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes Metab Res Rev Feb 2013, 29(2):166-170.
254. Habeeb N.M.M., Youssef O.I., Saab A.A.R., El Hadidi E.S. Adiponectin as a marker of complications in type I diabetes. Indian Pediatr Apr 2012, 49(4):277-280.
255. Saraheimo M., Forsblom C., Thorn L., Wadén J., Rosengård-Bärlund M., Heikkilä O., et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care Jun 2008, 31(6):1165-1169.
256. Forsblom C., Thomas M.C., Moran J., Saraheimo M., Thorn L., Wadén J., et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med Oct 2011, 270(4):346-355.
257. Geyikli I., Keskin M., Kör Y., Akan M. Increased resistin serum concentrations in patients with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013, 5(3):189-193.
258. Pang T.T.L., Chimen M., Goble E., Dixon N., Benbow A., Eldershaw S.E., et al. Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetes. J Clin Endocrinol Metab Mar 2013, 98(3):E418-E428.
259. Wijesekara N., Krishnamurthy M., Bhattacharjee A., Suhail A., Sweeney G., Wheeler M.B. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem Oct 29 2010, 285(44):33623-33631.
260. Matarese G., Sanna V., Lechler R.I., Sarvetnick N., Fontana S., Zappacosta S., et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes May 2002, 51(5):1356-1361.
261. Brown J.E.P., Onyango D.J., Dunmore S.J. Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett Jul 10 2007, 581(17):3273-3276.
262. Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol Feb 2013, 133(2):377-385.
263. Ni C., Chiu M.W. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol Jan 2014, 7:119-132.
264. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstad T., Margolis D.J. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol Nov 2004, 51(5):704-708.
265. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med Jul 30 2009, 361(5):496-509.
266. Raychaudhuri S.K., Maverakis E., Raychaudhuri S.P. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014, 13(4-5):490-495.
267. Griffiths C.E.M., Barker J.N.W.N. Pathogenesis and clinical features of psoriasis. Lancet Jul 21 2007, 370(9583):263-271.
268. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica Jan 1986, 172(6):298-304.
269. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes Jan 2012, 2:e54.
270. Russolillo A., Iervolino S., Peluso R., Lupoli R., Di Minno A., Pappone N., et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) Jan 2013, 52(1):62-67.
271. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses'' Health Study II. Arch Intern Med. 2007, 167(15):1670-1675.
272. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol Jul 2005, 125(1):61-67.
273. Kumar S., Han J., Li T., Qureshi A.A. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol Oct 2013, 27(10):1293-1298.
274. Love T.J., Zhu Y., Zhang Y., Wall-Burns L., Ogdie A., Gelfand J.M., et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis Aug 2012, 71(8):1273-1277.
275. Li W., Han J., Qureshi A.A. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis Aug 2012, 71(8):1267-1272.
276. Soltani-Arabshahi R., Wong B., Feng B.-J., Goldgar D.E., Duffin K.C., Krueger G.G. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol Jul 2010, 146(7):721-726.
277. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol Dec 2005, 141(12):1527-1534.
278. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol Sep 2008, 159(4):895-902.
279. Carrascosa J.M., Rocamora V., Fernandez-Torres R.M., Jimenez-Puya R., Moreno J.C., Coll-Puigserver N., et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014, 105(1):31-44.
280. McDonough E., Ayearst R., Eder L., Chandran V., Rosen C.F., Thavaneswaran A., et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol May 2014, 41(5):887-896.
281. Solis M.Y., de Melo N.S., Macedo M.E.M., Carneiro F.P., Sabbag C.Y., Lancha Júnior A.H., et al. Nutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associated. Einstein (Sao Paulo). 2012, 10(1):44-52.
282. Brenaut E., Horreau C., Pouplard C., Barnetche T., Paul C., Richard M.-A., et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol Aug 2013, 27(Suppl. 3):30-35.
283. Torres T., Alexandre J.M., Mendonça D., Vasconcelos C., Silva B.M., Selores M. Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. Am J Clin Dermatol Apr 2014, 15(2):129-135.
284. Florin V., Cottencin A.C., Delaporte E., Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol Feb 2013, 27(2):e186-e190.
285. Renzo L.D.I., Saraceno R., Schipani C., Rizzo M., Bianchi A., Noce A., et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther. 2011, 24(4):446-451.
286. Jin Y., Zhang F., Yang S., Kong Y., Xiao F., Hou Y., et al. Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci Nov 2008, 52(2):123-129.
287. Li W.-Q., Han J.-L., Zhang M.-F., Qureshi A.A. Interactions between adiposity and genetic polymorphisms on the risk of psoriasis. Br J Dermatol Mar 2013, 168(3):639-642.
288. Takahashi H., Tsuji H., Takahashi I., Hashimoto Y., Ishida-Yamamoto A., Iizuka H. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci Jul 2009, 55(1):74-76.
289. Duarte G.V., de FSP Oliveira M., Cardoso T.M., Follador I., Silva T.S., Cavalheiro C.M.A., et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol Feb 2013, 52(2):177-181.
290. Tobin A.M., Hackett C.B., Rogers S., Collins P., Richards H.L., O'Shea D., et al. Body Mass Index, Waist Circumference and HOMA-IR correlate with PASI in psoriasis patients receiving phototherapy. Br J Dermatol Feb 23 2014.
291. Nikolopoulou A., Kadoglou N.P.E. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther Jul 2012, 10(7):933-939.
292. Horreau C., Pouplard C., Brenaut E., Barnetche T., Misery L., Cribier B., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol Aug 2013, 27(Suppl. 3):12-29.
293. Miller I.M., Ellervik C., Yazdanyar S., Jemec G.B.E. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol Dec 2013, 69(6):1014-1024.
294. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol Apr 2013, 68(4):654-662.
295. Debbaneh M., Millsop J.W., Bhatia B.K., Koo J., Liao W. Diet and psoriasis, part I: impact of weight loss interventions. J Am Acad Dermatol Jul 2014, 71(1):133-140.
296. Naldi L., Conti A., Cazzaniga S., Patrizi A., Pazzaglia M., Lanzoni A., et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014, 170(3):634-642.
297. Jensen P., Zachariae C., Christensen R., Geiker N.R.W., Schaadt B.K., Stender S., et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatology Jul 2013, 149(7):795-801.
298. Farias M.M., Achurra P., Boza C., Vega A., de la Cruz C. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg Jun 2012, 22(6):877-880.
299. Hossler E.W., Wood G.C., Still C.D., Mowad C.M., Maroon M.S. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol Mar 2013, 168(3):660-661.
300. Gisondi P., Del Giglio M., Di Francesco V., Zamboni M., Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr Nov 2008, 88(5):1242-1247.
301. Di Minno M.N.D., Peluso R., Iervolino S., Russolillo A., Lupoli R., Scarpa R. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis Jun 1 2014, 73(6):1157-1162.
302. Jensen P., Zachariae C., Christensen R., Geiker N.R.W., Schaadt B.K., Stender S., et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm Venereol Feb 20 2014.
303. Michalak-Stoma A., Pietrzak A., Szepietowski J.C., Zalewska-Janowska A., Paszkowski T., Chodorowska G. Cytokine network in psoriasis revisited. Eur Cytokine Netw Dec 2011, 22(4):160-168.
304. Bulló M., García-Lorda P., Megias I., Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res Apr 2003, 11(4):525-531.
305. Zhu K.-J., Zhang C., Li M., Zhu C.-Y., Shi G., Fan Y.-M. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol Jul 2013, 38(5):478-483.
306. Wang Y., Chen J., Zhao Y., Geng L., Song F., Chen H.-D. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol May 2008, 158(5):1134-1135.
307. Johnston A., Arnadottir S., Gudjonsson J.E., Aphale A., Sigmarsdottir A.A., Gunnarsson S.I., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol Aug 2008, 159(2):342-350.
308. Coimbra S., Oliveira H., Reis F., Belo L., Rocha S., Quintanilha A., et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol Dec 2010, 24(12):1386-1394.
309. Takahashi H., Tsuji H., Honma M., Ishida-Yamamoto A., Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res Mar 2013, 305(2):113-116.
310. Ozdemir M., Yüksel M., Gökbel H., Okudan N., Mevlitoğlu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol May 2012, 39(5):443-448.
311. Kawashima K., Torii K., Furuhashi T., Saito C., Nishio E., Nishida E., et al. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed Jun 2011, 27(3):152-155.
312. Nakajima H., Nakajima K., Tarutani M., Sano S. Clear association between serum levels of adipokines and T-helper 17-related cytokines in patients with psoriasis. Clin Exp Dermatol 2012, 38(1):66-70.
313. Cerman A.A., Bozkurt S., Sav A., Tulunay A., Elbaşi M.O., Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol Sep 2008, 159(4):820-826.
314. Xue K., Liu H., Jian Q., Liu B., Zhu D., Zhang M., et al. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro-a possible reason for increased severity of psoriasis in patients with a high body mass index. Exp Dermatol Jun 2013, 22(6):406-410.
315. Xue Y., Jiang L., Cheng Q., Chen H., Yu Y., Lin Y., et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One 2012, 7(10):1-11.
316. Gerdes S., Osadtschy S., Rostami-Yazdi M., Buhles N., Weichenthal M., Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis?. Exp Dermatol Jan 2012, 21(1):43-47.
317. Ismail S.A., Mohamed S.A. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol Aug 2012, 167(2):436-439.
318. Shibata S., Tada Y., Hau C., Tatsuta A., Yamamoto M., Kamata M., et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol Mar 2011, 164(3):667-670.
319. Shibata S., Saeki H., Tada Y., Karakawa M., Komine M., Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci Jul 2009, 55(1):62-63.
320. Takahashi H., Tsuji H., Takahashi I., Hashimoto Y., Ishida-Yamamoto A., Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol Nov 2008, 159(5):1207-1208.
321. Zhu K.-J., Shi G., Zhang C., Li M., Zhu C.-Y., Fan Y.-M. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol Jun 2013, 40(6):438-442.
322. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol Sep 2011, 25(9):1007-1011.
323. Montaudié H., Sbidian E., Paul C., Maza A., Gallini A., Aractingi S., et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol May 2011, 25(Suppl. 2):12-18.
324. Shibata N., Hayakawa T., Hoshino N., Minouchi T., Yamaji A., Uehara M. Effect of obesity on cyclosporine trough concentrations in psoriasis patients. Am J Health Syst Pharm Aug 1 1998, 55(15):1598-1602.
325. Maza A., Montaudié H., Sbidian E., Gallini A., Aractingi S., Aubin F., et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol May 2011, 25(Suppl. 2):19-27.
326. Clark L., Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol Mar 2008, 58(3):443-446.
327. Reich K., Gottlieb A., Kimaball A., Li S. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. J Am Acad Dermatol 2006, 54:AB215.
328. Gordon K., Korman N., Frankel E., Wang H., Jahreis A., Zitnik R., et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol Mar 2006, 54(3 Suppl. 2):S101-S111.
329. Menter A., Gordon K.B., Leonardi C.L., Gu Y., Goldblum O.M. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol Sep 2010, 63(3):448-456.
330. Di Minno M.N.D., Peluso R., Iervolino S., Lupoli R., Russolillo A., Scarpa R., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) Jan 2013, 65(1):141-147.
331. Lebwohl M., Yeilding N., Szapary P., Wang Y., Li S., Zhu Y., et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol Oct 2010, 63(4):571-579.
332. Al-mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 2014, 14(6):749-756.
333. Di Lernia V., Tasin L., Pellicano R., Zumiani G., Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat Dec 2012, 23(6):404-409.
334. Carrascosa J.M., Vilavella M., Garcia-Doval I., Carretero G., Vanaclocha F., Daudén E., et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol Jul 2014, 28(7):907-914.
335. McLeod D.S.A., Cooper D.S. The incidence and prevalence of thyroid autoimmunity. Endocrine Oct 2012, 42(2):252-265.
336. Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab Jul 2009, 94(6):1853-1878.
337. Vanderpump M.P.J. The epidemiology of thyroid disease. Br Med Bull Jan 2011, 99:39-51.
338. Caturegli P., De Remigis A., Rose N.R. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014, 13(4-5):391-397.
339. Burek C.L. Talor M V. Environmental triggers of autoimmune thyroiditis. J Autoimmun. 2009, 33(3-4):183-189.
340. Cogni G., Chiovato L. An overview of the pathogenesis of thyroid autoimmunity. Hormones (Athens). 2013, 12(1):19-29.
341. Rotondi M., Magri F., Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrinol Metab Feb 2011, 96(2):344-346.
342. Fox C.S., Pencina M.J., D'Agostino R.B., Murabito J.M., Seely E.W., Pearce E.N., et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med Mar 24 2008, 168(6):587-592.
343. Nyrnes A., Jorde R., Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes (Lond) Jan 2006, 30(1):100-105.
344. Michalaki M.A., Vagenakis A.G., Leonardou A.S., Argentou M.N., Habeos I.G., Makri M.G., et al. Thyroid function in humans with morbid obesity. Thyroid Jan 2006, 16(1):73-78.
345. Rotondi M., Leporati P., La Manna A., Pirali B., Mondello T., Fonte R., et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism?. Eur J Endocrinol Mar 2009, 160(3):403-408.
346. Radetti G., Kleon W., Buzi F., Crivellaro C., Pappalardo L., Iorgi N. Thyroid function and structure are affected in childhood obesity. J Clin Endocrinol Metab 2014, 93(12):4749-4754.
347. Knudsen N., Laurberg P., Rasmussen L.B., Bülow I., Perrild H., Ovesen L., et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab Jul 2005, 90(7):4019-4024.
348. Portmann L., Giusti V. Obesity and hypothyroidism: myth or reality?. Rev Med Suisse Apr 4 2007, 3(105):859-862.
349. de Moraes CM Moulin, Mancini M.C., de Melo M.E., Figueiredo D.A., Villares S.M.F., Rascovski A., et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg Oct 2005, 15(9):1287-1291.
350. Kok P., Roelfsema F., Langendonk J.G., Frölich M., Burggraaf J., Meinders A.E., et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab Aug 2005, 90(8):4659-4663.
351. Danforth E., Burger A. The role of thyroid hormones in the control of energy expenditure. Clin Endocrinol Metab Nov 1984, 13(3):581-595.
352. Duntas L.H., Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid 2013, 23(6):646-653.
353. Feldt-Rasmussen U. Thyroid and leptin. Thyroid May 2007, 17(5):413-419.
354. Seoane L.M., Carro E., Tovar S., Casanueva F.F., Dieguez C. Regulation of in vivo TSH secretion by leptin. Regul Pept Aug 25 2000, 92(1-3):25-29.
355. Oge A., Bayraktar F., Saygili F., Guney E., Demir S. TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. Endocr J Apr 2005, 52(2):213-217.
356. Marzullo P., Minocci A., Tagliaferri M.A., Guzzaloni G., Di Blasio A., De Medici C., et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid. J Clin Endocrinol Metab 2014, 95(8):3965-3972.
357. Ong K.K., Kuh D., Pierce M., Franklyn J.A. Childhood weight gain and thyroid autoimmunity at age 60-64years: the 1946 British Birth Cohort Study. J Clin Endocrinol Metab 2014, 98(4):1435-1442.
358. Wang S., Baidoo S.E., Liu Y., Zhu C., Tian J., Ma J., et al. T cell-derived leptin contributes to increased frequency of T helper type 17 cells in female patients with Hashimoto's thyroiditis. Clin Exp Immunol 2012, 171(1):63-68.
359. Figueroa-Vega N., Alfonso-Pérez M., Benedicto I., Sánchez-Madrid F., González-Amaro R., Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab Feb 2010, 95(2):953-962.
360. Shi Y., Wang H., Su Z., Chen J., Xue Y., Wang S., et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto's thyroiditis. Scand J Immunol Sep 2010, 72(3):250-255.
361. Rodrigues C.E.M., Vendramini M.B., Bueno C., Bonfá E., De Carvalho J.F., Paulo-sp S., et al. Adipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome. Clin Exp Rheumatol 2012, 30(6):871-878.
362. Gary T., Belaj K., Bruckenberger R., Hackl G., Hafner F., Froehlich H., et al. Primary antiphospholipid antibody syndrome - one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism. Obesity 2013, 21(9):463-466.
363. Gheita T., El-Gazzar I., El Shazly R., El-Din A., Abdel-Rasheed E., Bassyouni R. Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity. J Clin Immunol 2013, 33(1):297-301.
364. Filkovà M., Senolt L., Vencovsky J. The role of resistin in inflammatory myopathies. Curr Rheumatol Rep 2013, 15(6):336.